Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial (atovaquone‑proguanil combination) presented as a tablet for oral use. It is used to prevent and treat malaria infection caused by Plasmodium falciparum, including chloroquine‑resistant strains.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is an antimalarial medication indicated for the prevention and treatment of malaria caused by Plasmodium falciparum.

- Pre‑exposure prophylaxis: prevents malaria infection in travelers to endemic regions. - Post‑exposure prophylaxis: reduces risk of malaria after possible mosquito exposure. - Acute uncomplicated malaria: treats confirmed P. falciparum infection, including chloroquine‑resistant strains.

Malarone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the abdomen. - Diarrhoea: loose stools, usually self‑limiting. - Metallic taste: altered taste perception. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Severe hypersensitivity: including anaphylaxis or Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes or jaundice. - Haemolytic anaemia: especially in patients with G6PD deficiency. - Severe neutropenia: marked reduction in white blood cells. - Cardiac arrhythmia: rare QT‑interval prolongation. - Visual disturbances: blurred vision or photophobia.

Before prescribing Malarone, clinicians should consider several safety factors.

- Pregnancy: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: unknown safety; weigh infant risk against maternal benefit. - Renal impairment: dose adjustment may be required; monitor renal function. - Drug resistance: ensure adherence to full regimen to minimise resistance development. - Concomitant medications: review for potential interactions before initiation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Malarone can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampicin: markedly lowers plasma concentrations of both components. - Protease inhibitors (e.g., ritonavir): may increase atovaquone levels, risking toxicity. - Phenobarbital: induces metabolism, reducing drug exposure.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., azithromycin): may increase QT‑interval prolongation risk. - Sulfonamides: additive hypersensitivity potential. - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring.